Taxis Pharmaceuticals Overview
- Founded
- 2009
- Status
- Private
- Employees
- 14
- Latest Deal Type
- Later Stage VC
- (Upcoming)
- Latest Deal Amount
- $2.5M
- Investors
- 3
Taxis Pharmaceuticals General Information
Description
Developer of antibiotics and antiviral drugs designed to address the health crisis of antimicrobial resistance. The company offers antibiotics and therapeutic agents that employ novel mechanisms of action distinct from those currently in clinical use and target multidrug-resistant bacterial pathogens, thereby enabling hospitals to treat MRSA (Methicillin-Resistant Staphylococcus Aureus) affected patients effectively.
Contact Information
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Biotechnology
Primary Office
- 9 Deerpark Drive
- Monmouth Junction, NJ 08852
- United States
Taxis Pharmaceuticals Timeline
Taxis Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Later Stage VC | $2.5M | Upcoming | Generating Revenue | |||
| 7. Grant | 14-Jan-2020 | 00.00 | 000.00 | Completed | Generating Revenue | |
| 6. Later Stage VC | 09-Jan-2019 | 00.000 | 000.00 | Completed | Generating Revenue | |
| 5. Angel (individual) | 25-Sep-2017 | 000 | Cancelled | Generating Revenue | ||
| 4. Later Stage VC (Series B2) | 10-Mar-2017 | 00.00 | 000.00 | Completed | Generating Revenue | |
| 3. Angel (individual) | 22-Jul-2015 | 000 | 00.000 | 000.00 | Completed | Generating Revenue |
| 2. Angel (individual) | 13-Apr-2015 | $6.5M | $6.74M | 0000 | Completed | Generating Revenue |
| 1. Angel (individual) | 19-Apr-2010 | $237K | $237K | Completed | Startup |
Taxis Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00 | 00.00 | 00 |
| Series A | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
Taxis Pharmaceuticals Executive Team (4)
Taxis Pharmaceuticals Board Members (7)
| Name | Representing | Role | Since |
|---|---|---|---|
| Christopher Cimarusti | Taxis Pharmaceuticals | Board Member | 000 0000 |
| Edmond LaVoie Ph.D | Self | Co-Founder and Board Member | 000 0000 |
| Ernest Mario Ph.D | Taxis Pharmaceuticals | Board Member | 000 0000 |
| Gail McIntyre Ph.D | Self | Board Member | 000 0000 |
| Gregory Mario | Taxis Pharmaceuticals | Co-Founder, Chief Executive Officer, President and Board Member | 000 0000 |
Taxis Pharmaceuticals Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialTaxis Pharmaceuticals Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| CARB-X | University | 000 0000 | 000000 0 | ||
| Eagles Ketch | Asset Manager | Minority | 000 0000 | 000000 0 | |
| Ithaka Partners | Growth/Expansion | Minority | 000 0000 | 000000 0 |